Screening and discovering drugs for the treatment of infectious diseases is a crucial task, forming the core of combating infectious diseases and ensuring public health safety. Infectious diseases such as influenza, AIDS, and novel coronaviruses have the characteristic of rapid transmission, posing a significant threat to public health. Effective therapeutic drugs are not only hoped to cure or control the disease, but more importantly, they can slow down the spread of the virus and significantly reduce the risk of widespread outbreaks. Furthermore, in the face of the growing drug resistance of pathogens, the development of new drugs is particularly critical. Creative Biolabs is committed to supporting our clients in continuous screening and R&D in this field, accelerating the R&D process of infectious disease treatment drugs, and contributing to the global health cause.
Interfering nucleic acids are nucleic acid sequences that can interfere with the replication or expression of the genetic material of pathogens. For example, small interfering RNA (siRNA), microRNA (miRNA), and shRNA are the focus of research. They can specifically target the key genes of the pathogen, thereby blocking its life cycle or pathological process.
By designing specific RNA sequences (guide RNA) to pair with the target DNA sequence, researchers can precisely modify the genome of the host or pathogen. This method allows scientists to directly target key genes of the pathogen or alter host cells to make them more resistant to pathogen invasion.
This field focuses on identifying and developing antibodies or peptides that can specifically bind to pathogens. These molecules can directly neutralize the pathogen or activate the immune system to clear it. With various antibody production techniques and peptide library screening technologies, researchers can discover highly specific and effective candidate therapeutic agents.
The proactive identification of therapeutic targets for infectious diseases is essential for more effective treatment and better control of these illnesses. This process is intricate and multi-faceted, requiring a thorough understanding of the pathogen's biological properties and its interactions with the host. By targeting these mechanisms, interventions can either halt pathogen replication or reduce the damage it causes, enabling disease treatment and prevention. Furthermore, as pathogens continue to evolve and drug resistance increases, discovering candidate therapeutic targets is crucial to ensuring the ongoing effectiveness of current therapies and combating emerging infectious threats. Creative Biolabs, leveraging its extensive expertise, cutting-edge technology, and a highly skilled professional team, is dedicated to advancing the discovery of key therapeutic targets for infectious diseases.
A: Targeted therapies focus on precisely identified therapeutic targets—such as specific pathogen proteins or host cell pathways—allowing for greater efficacy and reduced side effects. In contrast, traditional broad-spectrum drugs may inadvertently affect healthy cells, leading to more adverse reactions. Targeted drugs aim to treat the disease.
A: Creative Biolabs develops a wide range of drug types, including interfering nucleic acids (such as siRNA and miRNA), genome editing tools that modify pathogen or host genomes, and antibodies/peptides that specifically target and neutralize pathogens. These therapies are designed to be more selective, effective, and safe compared to traditional treatments.
A: Interfering nucleic acids, such as siRNA, miRNA, and shRNA, are used by Creative Biolabs to specifically target and silence critical genes in pathogens, disrupting their replication or expression. This method effectively prevents the lifecycle of pathogens, making it a promising tool for treating infectious diseases with minimal side effects.
A: Creative Biolabs accelerates drug development by utilizing advanced technologies like high-throughput screening, RNA interference, and genomics. Our focus is on quickly identifying and validating promising drug candidates, enabling rapid responses to infectious disease outbreaks and advancing drug development from discovery to research.
